Biogen lays out three FDA decisions that could ramp up Alzheimer's drug launch
Since its approval in 2023, the Alzheimer's disease drug made by Biogen Inc. and Eisai has seen a lackluster launch. However, Biogen CEO Chris Viehbacher said on Tuesday that there are a “number of ...
FiercePharma3d
Analysts tip Eisai, Biogen and Lilly to drive eightfold explosion in Alzheimer's market value
GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...
PMLiVE5d
Biogen/Eisai announce FDA BLA acceptance for injectable Alzheimer’s drug
Biogen and Eisai have announced that the US Food and Drug Administration (FDA) has accepted a Biologics License Application ...
Seeking Alpha6d
Biogen, Eisai say injectable Alzheimer’s therapy granted FDA review
Biogen (NASDAQ ... announced that the U.S. Food and Drug Administration (FDA) accepted a marketing application for an injectable version of their Alzheimer’s therapy lecanemab.
Sarepta, Biogen drugs with accelerated approval under fire in FDA report
A report from the U.S. FDA's Office of Inspector General is calling into question the thoroughness of the agency's ...
Benzinga.com6d
FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi
FDA sets August 31, 2025, as the action date for Eisai and Biogen's Leqembi ... Leqembi is indicated for Alzheimer’s disease ...
Sage confirms Biogen’s bid to acquire remaining stake
Sage Therapeutics (SAGE) stock jumped on Friday as Biogen (BIIB) made a bid to acquire the stake it currently doesn't own for ...
Becker's Hospital Review5d
Watchdog flags flaws in FDA's fast-track drug approvals
The OIG report points to gaps in documentation and decision-making transparency, particularly in the case of Aduhelm, where FDA records indicated only 13 meetings with Biogen, but congressional ...
The Boston Globe10d
Alzheimer’s drugs eyed as next big obesity-like opportunity
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025. Companies including Biogen Inc. and Eli ...
Bloomberg on MSN10d
Alzheimer’s Drugs Eyed by Investors Seeking Obesity-Like Gains
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Chattanooga Times Free Press7d
Alzheimer’s drugs eyed as next big obesity-like opportunity
Firms developing Alzheimer's drugs have already seen big peaks and troughs. Biogen shares soared 44% on a single day in November 2020 after news that an experimental drug appeared to be effective ...